SCHEMBL24148685

SCHEMBL24148685

C[C@H](NP(=O)(Oc1ccc(C(C)(C)C)cc1)Oc1c(F)c(F)c(F)c(F)c1F)C(=O)OCc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ BTN3A1 O00481 6/20 0.51
▸ PLAU P00749 1/20 0.44
▸ ELANE P08246 2/20 0.43
▸ POLB P06746 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ PRTN3 P24158 2/20 0.41
▸ MEN1 O00255 3/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ LMNA P02545 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ RAB9A P51151 1/20 0.37
▸ KLK1 P06870 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22105034 0.92 BTN3A1 (0.53) BTN3A1PLAUELANEPRTN3MEN1
SCHEMBL18973504 0.92 BTN3A1 (0.53) BTN3A1PLAUELANEPRTN3MEN1
SCHEMBL18953088 0.92 BTN3A1 (0.53) BTN3A1PLAUELANEPRTN3MEN1
SCHEMBL6567927 0.92 BTN3A1 (0.58) BTN3A1PLAUELANEPOLBGAA
SCHEMBL22105334 0.92 BTN3A1 (0.53) BTN3A1PLAUELANEPRTN3MEN1
SCHEMBL19894592 0.88 BTN3A1 (0.49) BTN3A1ELANEGAAPRTN3MEN1
SCHEMBL15593268 0.88 BTN3A1 (0.49) BTN3A1ELANEGAAPRTN3MEN1
SCHEMBL24149229 0.87 BTN3A1 (0.41) BTN3A1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL24149402 0.86 BTN3A1 (0.36) BTN3A1MEN1KMT2AL3MBTL1NPC1
SCHEMBL24148909 0.85 BTN3A1 (0.43) BTN3A1POLBGAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260035394-A1 1`-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF GILEAD SCIENCES INC (US) 2026-02-05 — — US disclosed
US-12404289-B2 1′-cyano nucleoside analogs and uses thereof GILEAD SCIENCES, INC. (US) 2025-09-02 — — US disclosed
US-20240287109-A1 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF GILEAD SCIENCES, INC. 2024-08-29 — — US disclosed
US-11939347-B2 1′-cyano nucleoside analogs and uses thereof GILEAD SCIENCES, INC. (US) 2024-03-26 — — US disclosed
EP-4172160-A2 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2023-05-03 — — EP disclosed
US-20230040586-A1 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF GILEAD SCIENCES, INC. 2023-02-09 — — US disclosed
US-20230040586-A1 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF GILEAD SCIENCES, INC. 2023-02-09 — — US disclosed
WO-2021262826-A2 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2021-12-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287109-A1 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF TYMP, PNP, DUT BTN3A1 3427/4885PLAU 2086/4885ELANE 519/4885
US-12404289-B2 1′-cyano nucleoside analogs and uses thereof TYMP, PNP, DUT BTN3A1 3685/4885PLAU 2155/4885ELANE 559/4885
US-20230040586-A1 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF TYMP, PNP, DUT BTN3A1 3427/4885PLAU 2086/4885ELANE 519/4885
US-11939347-B2 1′-cyano nucleoside analogs and uses thereof TYMP, PNP, DUT BTN3A1 3685/4885PLAU 2155/4885ELANE 559/4885
US-20260035394-A1 1`-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF PNP, SLC28A1, SLC29A1 BTN3A1 3686/4885PLAU 1671/4885ELANE 3466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback